Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME)

• Locally advanced non-metastatic carcinoma of the oropharynx limited to T3 and T4 (whatever the N) and N2-N3 (whatever the T)(AJCC stage III-IV)
• Age ≥ 18 years and ≤ 75 years
• Performance status (WHO ≤ 2)
• Renal, hepatic and cardiovascular functions allowing systemic treatment administration
• Adapted stomatologic care
• Signed informed consent form
• Membership or beneficiary of a national insurance scheme

Exclusion Criteria:

• Both parotids totally included in the target volume
• Stages T1 or T2 with positive node disease N1
• Neoadjuvant chemotherapy
• Exereses of primitive tumor and/or nodes
• History of other cancer within 5 years (except for basocellular epithelioma and cervical)
• Previous neck radiotherapy
• Platinum salts, 5FluoroUracile (5FU) agents or cetuximab chemotherapy
• Unstable diseases (cardiovascular, renal, pulmonary, systemic lupus or sclerodermia) incompatible with study participation
• Patient participating in other therapeutic trial with experimental drug, 30 days before the inclusion.
• Patient already recruited in another biomedical research ( non interventional study is authorized)
• Pregnant or breast feeding patients
• Patient deprived of liberty, under tutorship, guardianship or placed under judicial protection
• Patient is deemed incapable of giving informed consent
• Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls.